Evidence map›Paper›PMID 21382335›Full record

ReviewActa tropica2012

Malaria in the Greater Mekong Subregion: heterogeneity and complexity.

Liwang Cui, Guiyun Yan, Jetsumon Sattabongkot, Yaming Cao, Bin Chen, Xiaoguang Chen, Qi Fan, Qiang Fang, Somchai Jongwutiwes, Daniel Parker and 10 more

Abstract readReview
In one paragraph

Review in Acta tropica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 1 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 1 synthesis or guideline pooled it, 298 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Parasite epidemiology and control · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 4 countries.

Liwang CuiDepartment of Entomology, The Pennsylvania State University, University Park, 16801, USA. luc2@psu.edu
Guiyun Yan
Jetsumon Sattabongkot
Yaming Cao
Bin Chen
Xiaoguang Chen
Qi Fan
Qiang Fang
Somchai Jongwutiwes
Daniel Parker
Jeeraphat Sirichaisinthop
Myat Phone Kyaw
Xin-zhuan Su
Henglin Yang
Zhaoqing Yang
Baomin Wang
Jianwei Xu
Bin Zheng
Daibin Zhong
Guofa Zhou
University of California, Irvine · USChongqing Normal University · CNYunnan Institute of Parasitic Diseases · CNArmed Forces Research Institute of Medical Science · THBengbu Medical College · CNChina Agricultural University · CNChina Medical University · CNChulalongkorn University · THKunming Medical University · CNMyanmar Oxford Clinical Research Unit · MMNational Institute for Parasitic Diseases · CNNational Institute of Allergy and Infectious Diseases · USPennsylvania State University · USSouthern Medical University · CN

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
Intramural NIH HHSNIAID NIH HHS U19 AI089672
6 · The paper itself

Abstract

The Greater Mekong Subregion (GMS), comprised of six countries including Cambodia, China's Yunnan Province, Lao PDR, Myanmar (Burma), Thailand and Vietnam, is one of the most threatening foci of malaria. Since the initiation of the WHO's Mekong Malaria Program a decade ago, malaria situation in the GMS has greatly improved, reflected in the continuous decline in annual malaria incidence and deaths. However, as many nations are moving towards malaria elimination, the GMS nations still face great challenges. Malaria epidemiology in this region exhibits enormous geographical heterogeneity with Myanmar and Cambodia remaining high-burden countries. Within each country, malaria distribution is also patchy, exemplified by 'border malaria' and 'forest malaria' with high transmission occurring along international borders and in forests or forest fringes, respectively. 'Border malaria' is extremely difficult to monitor, and frequent malaria introductions by migratory human populations constitute a major threat to neighboring, malaria-eliminating countries. Therefore, coordination between neighboring countries is essential for malaria elimination from the entire region. In addition to these operational difficulties, malaria control in the GMS also encounters several technological challenges. Contemporary malaria control measures rely heavily on effective chemotherapy and insecticide control of vector mosquitoes. However, the spread of multidrug resistance and potential emergence of artemisinin resistance in Plasmodium falciparum make resistance management a high priority in the GMS. This situation is further worsened by the circulation of counterfeit and substandard artemisinin-related drugs. In most endemic areas of the GMS, P. falciparum and Plasmodium vivax coexist, and in recent malaria control history, P. vivax has demonstrated remarkable resilience to control measures. Deployment of the only registered drug (primaquine) for the radical cure of vivax malaria is severely undermined due to high prevalence of glucose-6-phosphate dehydrogenase deficiency in target human populations. In the GMS, the dramatically different ecologies, diverse vector systems, and insecticide resistance render traditional mosquito control less efficient. Here we attempt to review the changing malaria epidemiology in the GMS, analyze the vector systems and patterns of malaria transmission, and identify the major challenges the malaria control community faces on its way to malaria elimination.

Indexed as

AnimalsAnophelesAntimalarialsAsia, SoutheasternDisease EradicationDrug Resistance, MultipleHumansInsecticide ResistanceInsecticide-Treated BednetsInsect VectorsInternational CooperationMalariaMosquito ControlPlasmodiumPyrethrinsAntimalarialsPyrethrins

Identifiers

PMID21382335
PMCPMC3132579
OpenAlexW2082040429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.